Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of psychopharmacology"
DOI: 10.1177/02698811211050549
Abstract: BACKGROUND Olanzapine is one of the most commonly used antipsychotic drugs; however, its metabolic disorders are the main obstacle in the clinic. Olanzapine is a potent antagonist of the M3 acetylcholine muscarinic receptor (M3R), while… read more here.
Keywords: cevimeline treatment; olanzapine induced; treatment; metabolic disorders ... See more keywords